At this point, it's not about the PPS and all about on adding value to Elite and to build its diversified drug pipeline. The PPS would follow according to increasing sales and net income gains, which should eventually come in time. But the pharmaceutical industry is capital intensive, which requires substantial financial and operational resources. This is where the team of Hakim and Plassche come in to streamline the R & D and manufacturing processes to control expenses. Cheers!